Facilitated By

San Antonio Medical Foundation

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RAVULIZUMAB IN COMPLEMENT-INHIBITOR-NAIVE ADULT PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS

UT Health San Antonio

The UT Health San Antonio, with missions of teaching, research and healing, is one of the country’s leading health sciences universities.

Principal Investigator(s)
Bhavaraju-Sanka, Ratna K.
Funded by
ALEXION PHARMACEUTICALS
Research Start Date
Status
Active
Collaborative Project
Clinical Care
Drug Discovery
Neuroscience